# Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.

> **NCT04348383** · PHASE2 · COMPLETED · sponsor: **Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia** · enrollment: 156 (actual)

## Conditions studied

- COVID19

## Interventions

- **DRUG:** Defibrotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04348383
- **Lead sponsor:** Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-08
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348383, "Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04348383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*